James R. Goodhand

Exeter, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 59 publications

Clinical utility of pre-treatment four-digit-resolution HLA genotyping to guide anti-tumor necrosis factor choice and concomitant immunomodulator use.

Clinical utility of pre-treatment four-digit-resolution HLA genotyping to guide anti-tumor necrosis factor choice and concomitant immunomodulator use.

Journal: Journal of Crohn's & colitis

Published: December 21, 2025

Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential.

Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential.

Journal: Journal of Crohn's & colitis

Published: September 19, 2025

Editorial: LAMP Lights the Way-A Pragmatic Case for NUDT15 Screening Across Diverse Populations-Authors' Reply.

Editorial: LAMP Lights the Way-A Pragmatic Case for NUDT15 Screening Across Diverse Populations-Authors' Reply.

Journal: Alimentary pharmacology & therapeutics

Published: July 02, 2025

Clinical Utility and Cost-Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine-Induced Myelosuppression: A Genotype-First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease Bioresource.

Clinical Utility and Cost-Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine-Induced Myelosuppression: A Genotype-First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease Bioresource.

Journal: Alimentary pharmacology & therapeutics

Published: March 31, 2025

Understanding Anti-TNF Treatment Failure: Pre-Existing Antidrug Antibodies Are Common but Do Not Neutralize Drug Activity In Vitro or Influence Clinical Response to Infliximab or Adalimumab in Patients with Crohn Disease.

Understanding Anti-TNF Treatment Failure: Pre-Existing Antidrug Antibodies Are Common but Do Not Neutralize Drug Activity In Vitro or Influence Clinical Response to Infliximab or Adalimumab in Patients with Crohn Disease.

Journal: The journal of applied laboratory medicine

Published: March 27, 2025

Real-world effectiveness of upadacitinib in Crohn's disease: a UK multicentre retrospective cohort study.

Real-world effectiveness of upadacitinib in Crohn's disease: a UK multicentre retrospective cohort study.

Journal: Frontline gastroenterology

Published: February 09, 2024

Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or Tofacitinib.

Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or Tofacitinib.

Journal: Journal of Crohn's & colitis

Published: November 09, 2023

Baseline TREM-1 Whole Blood Gene Expression Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative Colitis or Crohn's Disease in the SERENE Studies.

Baseline TREM-1 Whole Blood Gene Expression Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative Colitis or Crohn's Disease in the SERENE Studies.

Journal: Journal of Crohn's & colitis

Published: October 06, 2023

Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study.

Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study.

Journal: The lancet. Gastroenterology & hepatology

Published: September 26, 2023

Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study.

Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study.

Journal: EClinicalMedicine

Published: July 13, 2023

Baseline Expression of Immune Gene Modules in Blood is Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease Patients.

Baseline Expression of Immune Gene Modules in Blood is Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease Patients.

Journal: Journal of Crohn's & colitis

Published: June 06, 2023

Anti-TNF Biologicals Enhance the Anti-Inflammatory Properties of IgG N-Glycome in Crohn's Disease.

Anti-TNF Biologicals Enhance the Anti-Inflammatory Properties of IgG N-Glycome in Crohn's Disease.

Journal: Biomolecules

Published: May 11, 2023

Showing 1-12 of 59

Last Updated: 09/26/2026